Author Archives: Marisa Wexler MS

New Spectroscopy Method May Help Identify CF Bacteria Faster

Scientists at the University of Southampton have created a new method that could be useful for rapidly identifying infectious bacteria in samples from people with cystic fibrosis (CF). Unlike currently used methods, this method does not require a time-consuming culture step where bacteria are grown in a laboratory. The…

Targeting Pathway With Ectoine May Help in Stabilizing CFTR Protein

A natural compound called ectoine may help to improve the stability of the CFTR protein by modulating the activity of a molecular signaling pathway called AREG-EGFR-ERK, a study reported. Ectoine is a stress-protection molecule with water-retaining and potentially anti-inflammatory properties. The researchers suggested that ectoine, given in combination with CFTR…

Canada Approves Trikafta for Children 6 and Older

Health Canada has expanded the approval of Vertex Pharmaceuticals‘ triple-combination modulator treatment Trikafta to cover children with cystic fibrosis (CF) as young as 6 who have at least one copy of the F508del mutation. Trikafta had been approved only for patients ages 12 and older in Canada. According to…

Europe Awaits Proposed New Framework for Sharing Health Data

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

KIT2014 Increased CFTR Modulator Effects in Preclinical Study

KIT2014, an experimental treatment that Kither Biotech is developing to treat cystic fibrosis (CF) and other lung diseases, was able to reduce inflammation, relax the airways, and improve the functionality of CFTR modulators in preclinical models, a study shows. Kither is planning to launch a Phase 1/2a clinical…